Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial.

MLA

Westin, Jason R., et al. “Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial.” Clinical Lymphoma, Myeloma & Leukemia, vol. 13, no. 2, Apr. 2013, pp. 99–105. EBSCOhost, https://doi.org/10.1016/j.clml.2012.11.002.

APA

Westin, J. R., Thompson, M. A., Cataldo, V. D., Fayad, L. E., Fowler, N., Fanale, M. A., Neelapu, S., Samaniego, F., Romaguera, J., Shah, J., McLaughlin, P., Pro, B., Kwak, L. W., Sanjorjo, P., Murphy, W. A., Jimenez, C., Toth, B., Dong, W., & Hagemeister, F. B. (2013). Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clinical Lymphoma, Myeloma & Leukemia, 13(2), 99–105. https://doi.org/10.1016/j.clml.2012.11.002

Chicago

Westin, Jason R., Michael A. Thompson, Vince D. Cataldo, Luis E. Fayad, Nathan Fowler, Michelle A. Fanale, Saatva Neelapu, et al. 2013. “Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial.” Clinical Lymphoma, Myeloma & Leukemia 13 (2): 99–105. doi:10.1016/j.clml.2012.11.002.